

## Flavanone metabolites decrease monocyte adhesion to TNF-alpha-activated endothelial cells by modulating expression of atherosclerosis-related genes

Audrey Chanet, Dragan Milenkovic, Sylvain Claude, Jeanette A. M. Maier, Muhammad Kamran Khan, Njara Rakotomanomana, Svitlana Shinkaruk, Annie M. Bérard, Catherine Bennetau- Pelissero, André Mazur, et al.

#### ▶ To cite this version:

Audrey Chanet, Dragan Milenkovic, Sylvain Claude, Jeanette A. M. Maier, Muhammad Kamran Khan, et al.. Flavanone metabolites decrease monocyte adhesion to TNF-alpha-activated endothelial cells by modulating expression of atherosclerosis-related genes. British Journal of Nutrition, 2013, 110 (4), pp.587-598. hal-02642629

# $\begin{array}{c} {\rm HAL~Id:~hal\text{-}02642629} \\ {\rm https://hal.inrae.fr/hal\text{-}02642629v1} \end{array}$

Submitted on 28 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



### Flavanone metabolites decrease monocyte adhesion to TNF- $\alpha$ -activated endothelial cells by modulating expression of atherosclerosis-related genes

Audrey Chanet<sup>1,2</sup>, Dragan Milenkovic<sup>1,2</sup>, Sylvain Claude<sup>1,2</sup>, Jeanette A. M. Maier<sup>3</sup>, Muhammad Kamran Khan<sup>4</sup>, Njara Rakotomanomana<sup>4</sup>, Svitlana Shinkaruk<sup>5</sup>, Annie M. Bérard<sup>6</sup>, Catherine Bennetau-Pelissero<sup>5</sup>, Andrzej Mazur<sup>1,2</sup> and Christine Morand<sup>1,2</sup>\*

(Submitted 11 April 2012 – Final revision received 8 November 2012 – Accepted 8 November 2012)

#### Abstract

Flavanones are found specifically and abundantly in citrus fruits. Their beneficial effect on vascular function is well documented. However, little is known about their cellular and molecular mechanisms of action in vascular cells. The goal of the present study was to identify the impact of flavanone metabolites on endothelial cells and decipher the underlying molecular mechanisms of action. We investigated the impact of naringenin and hesperetin metabolites at 0·5, 2 and 10 μM on monocyte adhesion to TNF-α-activated human umbilical vein endothelial cells (HUVEC) and on gene expression. Except hesperetin-7-glucuronide and naringenin-7-glucuronide (N7G), when present at 2 µM, flavanone metabolites (hesperetin-3'-sulphate, hesperetin-3'-glucuronide and naringenin-4'-glucuronide (N4'G)) significantly attenuated monocyte adhesion to TNF-α-activated HUVEC. Exposure of both monocytes and HUVEC to N4'G and N7G at 2 μM resulted in a higher inhibitory effect on monocyte adhesion. Gene expression analysis, using TaqMan Low-Density Array, revealed that flavanone metabolites modulated the expression of genes involved in atherogenesis, such as those involved in inflammation, cell adhesion and cytoskeletal organisation. In conclusion, physiologically relevant concentrations of flavanone metabolites reduce monocyte adhesion to TNF-α-stimulated endothelial cells by affecting the expression of related genes. This provides a potential explanation for the vasculoprotective effects of flavanones.

Key words: Flavanones: Metabolites: Monocyte adhesion: Gene expression: Endothelial cells



Atherosclerosis, a multifactorial disease of the large arteries and the leading cause of CVD, is characterised by inflammatory and oxidative stress involving chronic dysfunction of the endothelium. This altered function of endothelial cells is associated with both an imbalance in the production of vasodilators/vasoconstrictors and an increase in the expression of pro-inflammatory, chemotactic and adhesion molecules<sup>(1,2)</sup>. These changes facilitate the adhesion of circulating immune cells to the activated endothelium, and their subsequent migration into the arterial wall constitutes early events in the

atherogenic process. Once in the intima, monocytes differentiate into activated macrophages, which take up oxidised lipoproteins, leading to the formation of foam cells<sup>(3)</sup>.

A positive association between a high consumption of fruits and vegetables and a reduced risk of CVD has been described<sup>(4,5)</sup>. Among the protective bioactive compounds found in fruits and vegetables, polyphenols seem to be of particular interest. Indeed, epidemiological studies have established an inverse relationship between the intake of flavonoids, a subclass of polyphenols, and mortality from CVD<sup>(6)</sup>. Animal

Abbreviations: ACTR, actin-related protein; CCL2, chemokine (C-C motif) ligand 2; EZR, ezrin; H3/G, hesperetin-3/-glucuronide; H3/S, hesperetin-3/sulphate; H7G, hesperetin-7-glucuronide; H, hesperetin; HUVEC, human umbilical vein endothelial cell; ICAM-1, intercellular adhesion molecule 1; N4'G, naringenin-4'-glucuronide; N7G, naringenin-7-glucuronide; RAC, ras-related C3 botulinum toxin substrate 1; TLDA, TaqMan Low-Density Array; VCAM-1, vascular cell adhesion molecule 1.

<sup>&</sup>lt;sup>1</sup>INRA, UMR 1019, UNH, CRNH Auvergne, F-63000 Clermont-Ferrand, France

<sup>&</sup>lt;sup>2</sup>Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, BP 10448, F-63000, Clermont-Ferrand, France

<sup>&</sup>lt;sup>3</sup>Dipartimento di Scienze Cliniche Luigi Sacco, Università di Milano, Milano, Italy

<sup>&</sup>lt;sup>4</sup>INRA, UMR 408, Université d'Avignon, F-84000 Avignon, France

<sup>&</sup>lt;sup>5</sup>Université de Bordeaux – Bordeaux Sciences Agro, 33 175 Gradignan cedex, France

<sup>&</sup>lt;sup>6</sup>ERU «Facteurs de risque vasculaires», CHU-Université de Bordeaux 2, 146, rue Léo-Saignat, case 49, 33076 Bordeaux, France

<sup>\*</sup>Corresponding author: C. Morand, email christine.morand@clermont.inra.fr

studies have demonstrated that polyphenols may exert anti-atherogenic effects through anti-oxidative and anti-inflammatory actions that may prevent endothelial dysfunction<sup>(7)</sup>.

Flavanones are a subclass of flavonoids found specifically and abundantly in citrus fruits. Recently, a prospective study demonstrated a positive association between the dietary intake of flavanones and flavanone-rich foods and reduced risk of CHD and stroke<sup>(8,9)</sup>. In addition, a recent clinical trial established that flavanone supplementation in healthy, middle-aged, moderately overweight men improved postprandial microvascular endothelial reactivity and lowered diastolic blood pressure after 1 month<sup>(10)</sup>. In animal studies, flavanone supplementation has been reported to exert anti-atherogenic properties in various animal models of diet-induced atherosclerosis (11-13). Such effects have been associated with reduced expression of vascular cell adhesion molecule 1 (VCAM-1) and monocyte chemotactic protein-1 in the aorta<sup>(11)</sup>. We have also shown, in a recent study, that the antiatherogenic effect of flavanones was associated with decreased concentrations of plasma biomarkers of endothelial dysfunction and modulation of expression of genes involved in adhesion and transendothelial migration (13). Furthermore, the few studies that have investigated the effects of flavanones on endothelial cell activity in vitro have reported changes in the levels of cell adhesion molecules and reduced adhesion of monocytes to endothelial cells<sup>(14–16)</sup>. Altogether, these data suggest a beneficial role of flavanone consumption on vascular function.

Cell culture-based studies are important to identify the cellular and molecular mechanisms involved in flavanones' action regarding CVD prevention. However, to date, most of the studies performed have used supraphysiological concentrations of flavanones (aglycone or glycoside forms), which are not present in the circulation after citrus fruit consumption (14,15). Indeed, after ingestion, flavanone glycosides naturally present in citrus fruits are first hydrolysed in the distal part of the intestine by the microflora to release aglycones, which are then absorbed. In the intestinal cells, aglycone forms are subjected to phase II biotransformations (glucuronidation, sulphation and methylation), processes which continue in the liver<sup>(17)</sup>. Consequently, flavanones present in plasma are not native or aglycone forms, but almost exclusively conjugated metabolites. Such metabolites were identified in human subjects as being hesperetin-7-glucuronide (H7G), hesperetin-3'-sulphate (H3'S), hesperetin-3'-glucuronide (H3'G), naringenin-4'glucuronide (N4'G) and naringenin-7-glucuronide (N7G) after consumption of orange and grapefruit juice (18-20). Whether these metabolites at physiologically relevant concentrations have biological potencies remain unknown.

The aim of the present study was to investigate the effect of flavanone metabolites on endothelial cell function, particularly on monocyte adhesion on TNF-α-activated endothelial cells. Furthermore, to decipher the underlying molecular mechanisms, the impact of flavanone metabolites on the expression profile of genes and proteins involved in atherosclerosis development have been analysed.

#### Material and methods

#### Materials and chemicals

Naringenin and hesperetin were purchased from Extrasynthese. Flavanone glucuronides (H7G, H3'G and N7G) and H3'S were chemically synthesised<sup>(20)</sup>. Chemical structures of naringenin and hesperetin and their main conjugated forms are presented in Supplemental Fig. S1 (available online). Solutions of naringenin, hesperetin as well as of their conjugates were obtained by dissolving them in 50% ethanol in bidistilled water. TNF-α was obtained from R&D Systems and was dissolved in 0.1% PBS/bovine serum albumin (Pan Biotech) to obtain a stock solution of  $100 \,\mu g/ml$ .

#### Cell culture

Primary human umbilical vein endothelial cells (HUVEC; Lonza) were used at passage 5 and were cultured in a phenol-red-free endothelial growth medium supplemented with 2% fetal bovine serum, 0.4% fibroblast growth factor, 0.1% vascular endothelial growth factor, 0.1% heparin, 0.1% insulin-like growth factor, 0.1% ascorbic acid, 0.1% epidermal growth factor and 0.04% hydrocortisone (all from Lonza). Experiments were performed in twenty-four-well plates (Becton Dickinson).

A human monocytic cell line (U937) (American Type Culture Collection) was cultured in Roswell Park Memorial Institute medium (Pan Biotech) supplemented with 2% fetal bovine serum (Sigma). Both cultures were maintained at 37°C and 5% CO<sub>2</sub>.

#### Monocyte adhesion assay

HUVEC were allowed to proliferate until they reached 60-70% confluence. The medium was then replaced to expose the cells for 24 h to an experimental medium containing solvent alone (ethanol 0.5%, control wells and vehicle), flavanones or flavanone metabolites (0.5, 2 or 10 µm). At the end of the 24h period, the confluent monolayer was stimulated for 4h with  $0.1\,ng/ml$  TNF- $\alpha$  or PBS/bovine serum albumin (0·01‰, negative control). Following TNF-α stimulation,  $50 \,\mu l$  of a  $5 \times 10^6 / ml$  U937 cell suspension were added to each well and cells were further incubated for 1 h. Non-adhering U937 cells were rinsed away using 1 x PBS and the wells were fixed with 0.5% crystal violet in ethanol (Sigma). The number of attached U937 cells was counted for each well in three random microscopic fields defined by an eyepiece<sup>(21)</sup>. Triplicates for each condition were performed in three independent experiments.

In a second set of experiments, both HUVEC and U937 cells were pre-treated separately for 24h with flavanones or flavanone metabolites (2 µm). After 24 h, 50 µl of a suspension of  $5 \times 10^6$ /ml U937 cells, pre-exposed to flavanones or their metabolites, were added to the wells containing HUVEC pre-exposed to the same compounds and previously treated for 4h with TNF-α. The two cell types were co-incubated for 1h and the adhesion assay performed as described earlier.





The experiments were repeated three times in triplicate. The experimental approach is schematically represented in Fig. 1.

#### RNA extraction and complementary DNA synthesis

To collect RNA, sub-confluent HUVEC were exposed for 24 h to a medium containing solvent alone (ethanol 0.5%, control wells), flavanones or flavanone metabolites. The monolayer was stimulated for 5h with TNF-α (0·1 ng/ml) in order to expose the cells to TNF- $\alpha$  for the same time period as in the adhesion assay, where the HUVEC were activated with TNF-α for 4h prior to co-incubation with monocytes for a further 1 h. Following this step, the cells were rinsed twice with cold PBS and lysed (Qiagen). Samples were kept at -80°C before RNA extraction.

Total RNA was extracted using QIAGEN® RNeasy® Kits (Qiagen), according to the manufacturer's protocol. The quality of total RNA was monitored in 1% agarose gel by electrophoresis and RNA quantity was checked on a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). RT of total RNA was performed using a High Capacity cDNA RT kit (Applied Biosystems), each reaction mixture containing 1 µg RNA,  $1 \times RT$  buffer, 4 mm-deoxyribonucleoside triphosphates(dNTP) mix, 1 × random primers, 50 U RT and 20 U RNase inhibitor in a total volume of 20 µl. The RT reactions were run under the following conditions: 25°C for 10 min, 37°C for 120 min and 85°C for 5 s.

#### Real-time quantitative PCR

Impact of flavanones and their metabolites on the expression of genes in HUVEC were performed using the TaqMan Low-Density Array (TLDA) (Applied Biosystems). The TLDA contained primers for ninety-six genes of interest. Genes were chosen according to their role in atherosclerosis development from published articles (Table S1, available online).


A measure of 200 ng (2 µl) of complementary DNA was used in each sample and 98 µl of nuclease-free water together with 100 µl 2 × TagMan Universal PCR Master Mix (Applied Biosystems) were added for the quantitative real-time PCR measurements. This mixture was divided equally over two sample-loading ports of the TLDA. The arrays were centrifuged once (1 min, 1300 rpm at room temperature) to equally distribute the sample over the wells. Subsequently, the card was sealed to prevent an exchange between the wells. Quantitative PCR amplification was performed using an Applied Biosystems Prism 7900HT system (Applied Biosystems), with the following thermal cycler conditions: 2 min at 50°C and 10 min at 94.5°C, followed by forty cycles of 30 s at 97°C and 30 s at 59.7°C. Raw data were analysed using Sequence Detection System Software v2.4 (Applied Biosystems). Analyses were performed in triplicate.

#### Unsupervised modelling

The clustering analysis was performed on mRNA expression data. Unsupervised modelling was subsequently performed using hierarchical clustering, with the Euclidean distance for calculating the similarity between genes and the Ward's distance for the similarity between conditions using average linkage. Permutmatrix version 1.9.3 (http://www.lirmm.fr/~caraux/ PermutMatrix) was used for hierarchical clustering<sup>(22)</sup>.

#### Western blot analysis

For Western blot analysis of proteins, the same experimental conditions as for RNA extraction were used, i.e. the subconfluent HUVEC were exposed for 24h to a medium containing solvent alone (ethanol 0.5‰, control wells), flavanones or flavanone metabolites. The monolayer was stimulated for 5h with TNF- $\alpha$  (0.1 ng/ml) in order to expose the cell to TNF-α for the same time period as in adhesion assay, where the HUVEC were activated with TNF-α for 4h prior






Fig. 1. Schematic representation of in vitro experimental approach. (a) Experimental condition for monocyte adhesion assay. (b) Experimental condition for RNA and protein extraction. HUVEC, human umbilical vein endothelial cells. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)




to co-incubation with monocytes for further 1h. Following this step, the cells were rinsed twice with cold PBS and the total proteins were extracted using lysis buffer containing 150 mm-NaCl, 10 mm-Tris-HCl, 1 mm-ethylene glycol tetraacetic acid, 1 mm-EDTA, 100 mm-sodium fluoride, 4 mmsodium pyrophosphate, 2 mm-sodium orthovanadate, 1% Triton X100 and 0.5% IGEPAL CA-630 (all were obtained from Sigma).

After washing with PBS, the cells were lysed using the lysis buffer supplemented with 1% protease inhibitor cocktail (Sigma) and the lysates were frozen at -80°C overnight after centrifugation at 14 000 rpm for 30 min at 4°C. Protein concentrations were determined using the BCA Protein Assay Kit (Interchim). A measure of 10 µg of total proteins was electrophoretically separated on 8% polyacrylamide gels and transferred for 1h on to nitrocellulose membranes Genetex (Euromedex). The membranes were then blocked for 1h with 5% bovine serum albumin and Tris-buffered saline/0·1% Tween 20. After washing with Tris-buffered saline/0·1% Tween 20, the membranes were incubated with primary antibodies against intercellular adhesion molecule 1 (ICAM-1) (1/2000), VCAM-1 (1/2000), E-Selectin (1/2000), vinculin (1/2000) and β-actin (1/10000); all the reagents were obtained from Genetex (Euromedex). The membranes were then incubated with secondary fluorescent goat antirabbit and goat anti-mouse IgG (H + L) antibodies (1/2000) from Genetex (Euromedex). Proteins were visualised by the Odyssey Li-Cor detection system (LI-COR) and the density of the signals was quantified using Odyssey software (LI-COR). Samples were normalised to the housekeeping protein  $\beta$ -actin. The expression of  $\beta$ -actin was used as the control for protein loading.

#### Statistical analyses

Adhesion assay. Data were analysed by one-way ANOVA, after Bartlett's test of homogeneity of variance and the Kolmogorov-Smirnov test for Gaussian distribution, followed by Dunnett's post boc test. A value of P < 0.05 was considered significant. The software used was GraphPad InStat version 3.06 (GraphPad Software, Inc.).

Gene expression analysis. Relative gene expression levels of each gene were calculated by the comparative  $C_t$  method and the results were normalised to actin expression for each sample. Statistical analyses of the normalised gene expression data were performed using Dataassist software (Applied Biosystems; http://products.appliedbiosystems.com/ab/en/US/ adirect/ab?, http://cmd=catNavigate2&catID=606580). The software utilises the comparative  $C_{\rm T}$  ( $\Delta\Delta C_{\rm T}$ ) method to calculate quantitative relative gene expression across a large number of genes and samples. The software uses a refined Grubbs' outlier test to remove the outliers among technical replicates, provides a metric to measure control gene stability based on the geNorm algorithm to assist with endogenous control selection and allows the use of single or multiple control genes for data normalisation. P<0.05 was taken to imply statistical significance.



#### **Results**

#### Impact of pre-exposure of endothelial cells to flavanone metabolites on monocyte adhesion

Flavanones and their conjugated metabolites at a concentration of 10 µM did not significantly influence cell viability compared with flavanone-free control solution (Supplementary data 1, available online).

As expected, a small number of monocytes adhered to unstimulated HUVEC and treatment with TNF-α significantly increased cell adhesion (280%, P<0.05) compared with unstimulated control cells (Fig. 2). Pre-exposure of HUVEC to naringenin and N4'G (2 and 10 µm) for 24 h significantly reduced monocyte adherence to TNF- $\alpha$ -activated endothelial cells (-20%) (Fig. 2). A reduction in cell adhesion was also observed with N7G, but only at 10 µM concentration (-24%). Pre-exposure of HUVEC to hesperetin (H), H3'G and H3'S also significantly reduced monocyte adhesion to activated endothelial cells at  $2 \mu M$  concentration (-23, -21 and -14%, respectively), but this effect was no longer observed at a concentration of 10 µm. Finally, exposure to H7G did not produce any change in cell adhesion.

#### Impact of pre-exposure of both endothelial cells and monocytes to flavanone metabolites on cell adhesion


When both HUVEC and U937 cells were pre-exposed for 24 h with N4'G and N7G (2 μм), the magnitude of the inhibition of cell adhesion was higher compared with the respective conditions with non-exposed monocytes (Fig. 3). For the two aglycone forms as well as for hesperetin metabolites, no differences were observed as compared with non-pretreated U937 cells.

#### Impact of flavanones and their metabolites on gene expression in TNF- $\alpha$ -stimulated endothelial cells

To evaluate the impact of flavanones and their metabolites on the expression of targeted genes, quantitative PCR was performed using TLDA. Out of ninety-six genes evaluated, eleven were identified as not expressed. Analysis of obtained quantitative PCR raw data by Dataassist software (Applied Biosystems) revealed that the expression of fourteen genes was significantly modified by TNF-α. Among these fourteen genes, expression of thirteen was up-regulated and the expression of one gene was down-regulated. Genes modulated by TNF-α are implicated in different cellular processes, such as cell adhesion (ICAM-1 and CDH5 (cadherin 5, type 2 - vascular endothelium)), inflammation and chemotaxis (N-FKB1 and chemokine (C-C motif) ligand 2











Fig. 2. Effect of incubation of endothelial cells with flavanones on monocyte adhesion. Human umbilical vein endothelial cells (HUVEC) were stimulated with TNF-α for 4h after culture with or without (a) naringenin (Nar) and its conjugates (naringenin-4'-glucuronide (N4'G) and naringenin-7-glucuronide (N7G)) or (b) hesperetin (Hesp) and its conjugates (hesperetin-3'-glucuronide (H3'G); hesperetin-3'-sulphate (H3'S) and hesperetin-7-glucuronide (H7G)) for 24h. Monocytes were co-incubated for 1h and their adhesion to HUVEC counted. Monocyte adhesion is presented as a percentage of U937 to HUVEC. Values are means of three independent experiments, with standard deviations represented by vertical bars. Mean values were significantly different (by oneway ANOVA followed by Dunett's post hoc test): \*P<0.05, \*\*P<0.01. (A colour version of this figure can be found online at http://www.journals. cambridge.org/bjn)

(CCL2)) or cytoskeleton organisation (actin-related protein (ACTR)2, ezrin (EZR) and RAC-1) (Fig. 4).

This gene expression study also revealed that the 24 h exposure of HUVEC to flavanones, aglycones or their metabolites at a physiologically relevant concentration (2 µм) before activation with TNF- $\alpha$  significantly modulated the expression of genes. H3/S modulated the expression of the highest number of genes, as twenty genes have been identified as differentially expressed after 24h pre-exposition to this metabolite; H, H3'G, H7G and H3'S modulated the expression of fourteen, seven, six and twenty genes, respectively (Table S2, available online). Naringin and its metabolites, N4'G and N7G, modulated the expression of three, nine and four genes, respectively (Table S2, available online). Taken as a whole, modulated genes are implicated in different cellular functions; for example, CD99 molecule (CD99), catenin (cadherin-associated protein), beta 1, 88 kDa (CTNNB1), kelch-like ECH-associated protein 1 (KEAP1), moesin (MSN), integrin, beta 1 (ITGB1) and von Willebrand factor (VWF) are involved in cell-cell adhesion; ACTR2, ACTR3, plateletderived growth factor receptor, alpha polypeptide (PDGFRA), p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1), p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4), EZR and protein phosphatase 1, regulatory subunit 12B (PPP1R12B) in actin cytoskeleton organisation; ras homolog family member A (RHOA) and cyclin-dependent kinase inhibitor 1 (CDKN1A) in Rho signalling transduction; and CCL2, NFKB1 and mitogen-activated protein kinase 14 (MAPK14) in chemotaxis. As presented earlier, some of the cellular processes affected by flavanone metabolites have also been identified from differentially expressed genes after stimulation of HUVEC with TNF- $\alpha$  compared with non-stimulated cells. Furthermore, most of the aforementioned genes have been identified as regulated by more than one metabolite, while a








Fig. 3. Impact of pre-exposure of both endothelial cells and monocytes to flavanones on cell adhesion. Human umbilical vein endothelial cells (HUVEC) were stimulated with TNF- $\alpha$  for 4 h after incubation without or with (a) naringenin (Nar) and its conjugates (naringenin-4'-glucuronide (N4'G) and naringenin-7-glucuronide (N7G)) or (b) hesperetin (Hesp) and its conjugates (hesperetin-3'-glucuronide (H3'G); hesperetin-3'-sulphate (H3'S) and hesperetin-7-glucuronide (H7G)) at 2 μM for 24 h. Prior to the adhesion assay, monocytes (U937) were pre-incubated or not with (a) Nar and its conjugates or with (b) Hesp and its conjugates at 2 μM for 24 h, co-incubated for 1 h and their adhesion to HUVEC investigated. Monocyte adhesion is presented as a percentage of U937 to HUVEC. Values are means of three independent experiments, with standard deviations represented by vertical bars. Mean values were significantly different (by one-way ANOVA followed by Dunett's post hoc test): \*P<0.01, \*\*\* P<0.01, \*\*\* P<0.01. ■, Exposure to HUVEC only; ■, exposure to both HUVEC and monocytes. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)

few of them, such as KEAP1 or CCL2, have been identified as modulated by only one of the studied metabolites.

The obtained expression profiles of the studied genes have been clustered using the hierarchical unsupervised method using PermutMatrix software. In this cluster, vertical lines represent different experimental conditions, while horizontal lines present the studied genes (Fig. 4). The cluster revealed two distinct groups, one corresponding to the expression profile of cells stimulated with TNF-α, noted A, and the second one containing the expression profiles of cells preexposed to flavanones and then stimulated with TNF- $\alpha$ , noted B. This cluster revealed that TNF- $\alpha$  stimulation of HUVEC induced up-regulation of most of the genes, while pre-exposure of HUVEC to flavanones results in a global down-regulation of gene expression.

#### Effect of flavanones and their metabolites on cell adhesion protein expression levels in TNF- $\alpha$ -stimulated endothelial cells

Together with gene expression analysis, protein expression was also analysed for flavanones and their metabolites that significantly reduced monocyte adhesion to HUVEC at 2 µM concentration (H, H3'G, H3'S, naringenin and N4'G). Western blot analysis was performed for cell adhesion molecule proteins (ICAM1, VCAM1 and E-selectin) and cytoskeleton organisation protein (vinculin). The treatment of HUVEC with H, H3'S and naringenin (2 μм) for 24 h prior to exposure to TNF- $\alpha$  induced a significantly decreased protein level of vinculin (Fig. 5), whereas no impact of the tested metabolites was observed on cell adhesion protein levels (Fig. S2, available online).








Fig. 4. Two-dimensional hierarchical clustering analysis of mRNA profiles in human umbilical vein endothelial cells (HUVEC) under different conditions (TNF- $\alpha$   $\nu$  control, TNF- $\alpha$ -stimulated HUVEC treated with flavanones  $\nu$ . TNF- $\alpha$  alone-stimulated HUVEC). Flavanones, aglycones (hesperetin (H) and naringenin (N)) and metabolites (hesperetin-3'-glucuronide (H3'G), hesperetin-3'-sulphate (H3'S), hesperetin-7-glucuronide (H7G), naringenin-4'-glucuronide (N4'G) and naringenin-7-glucuronide (N7G)) were used at  $2 \mu$  concentration. mRNA are represented on the vertical axis, while different tested conditions are plotted on the horizontal axis. Red or green colours indicate up-regulation and down-regulation, respectively. Results are from three independent experiments. Significance was determined by the comparative  $C_T$  ( $\Delta \Delta C_T$ ) method. Yellow squares ( $\square$ ): P < 0.05, blue dotted squares ( $\square$ ): P < 0.1. See Appendix 1 and Table S1 (available online) for a list of names and abbreviations. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)




Fig. 5. Effect of flavanones and their metabolites on vinculin (VCL) protein expression in human umbilical vein endothelial cells (HUVEC). HUVEC were pre-treated with hesperetin (H), hesperetin-3'-glucuronide (H3'G), hesperetin-3'-sulphate (H3'S), naringenin (N) or naringenin-4'-glucuronide (N4'G) for 24 h followed by induction with TNF-α. Expression of VCL protein in cells was evaluated by immunoblotting. Values are means, with their standard errors represented by vertical bars, n 3. \*Mean value was significantly different from that of TNF- $\alpha$  control without flavanone pre-treatment (P<0.05).

#### Discussion

In a previous in vivo study, we demonstrated that flavanones consumed at a nutritional dose reduced lesion development in a mouse model of diet-induced atherosclerosis (23). Transcriptomic data analysis from aorta revealed that this effect might be mediated by flavanone-induced altered expression of genes that govern monocyte adhesion to endothelial cells and their subsequent trans-endothelial migration into the intima of aorta. Thus, to gain further insights into the role of flavanones on cardiovascular protection, the present study aimed to investigate the direct effects of circulating flavanone metabolites on endothelial cell function. Experimental conditions were set in order to reproduce the vascular environment observed after the consumption of flavanonerich foods. From this perspective, flavanone metabolites that had been identified in human plasma after the consumption of orange and grapefruit juice were used. These metabolites were employed at physiologically relevant concentrations and were incubated with endothelial cells for 24 h, which corresponds to the time required for flavanones to be excreted following their ingestion<sup>(23)</sup>. Furthermore, HUVEC were used as a model of human endothelial cells and were exposed to inflammatory stress to mimic a pro-atherogenic environment. To induce inflammatory stress, TNF- $\alpha$ , a pro-inflammatory cytokine capable of inducing endothelial dysfunction and whose circulating concentrations have been identified as elevated in plasma of patients at risk of CVD, was chosen<sup>(24)</sup>. The present study showed that, except H7G and N7G, flavanone metabolites were effective at 2 µM to attenuate monocyte adhesion to TNF- $\alpha$ -activated endothelial cells, the first step of atherogenesis. This concentration has been reported in human plasma following grapefruit or orange consumption (25,26) and can be therefore considered as nutritionally achievable. In the present experimental conditions, we failed to observe a dose-dependent effect of flavanone metabolites on cell adhesion. A similar observation has been previously reported for other flavonoids, both in endothelial and in immune cells<sup>(27,28)</sup>. Data from the present study suggest that metabolites could be as potent as their aglycones in preventing monocyte adhesion to activated HUVEC. Furthermore, it is noteworthy that flavanone metabolites conjugated on the B ring seem to be more efficient in reducing cell adhesion than those substituted on the A ring. This suggests that the biological potency of metabolites depends on the position of conjugation rather than on the nature of the substituent (sulphate or glucuronide). Overall, the ability of flavanone metabolites to decrease monocyte adhesion to activated endothelial cells may be one of the mechanisms underlying the anti-atherogenic activity of flavanones in vivo (10-13).

When present in blood circulation, flavanone metabolites may interact with endothelial cells as well as with immune cells, such as monocytes. Consequently, to fit as closely as possible with physiological conditions, it has been examined to what extent the pre-exposure of both endothelial cells and monocytes to flavanone metabolites may affect the cell adhesion process. The obtained data showed that exposure of monocytes to N4'G and N7G potentiated the inhibitory





effect of flavanones on monocyte adhesion to HUVEC when compared with a condition in which only HUVEC were preexposed to metabolites (Fig. 3). This finding revealed that circulating monocytes also constitute cellular targets for naringenin metabolites, which affect the ability of monocytes to interact with endothelial cells. In agreement, we have previously shown in human subjects that hesperidin supplementation modulated gene expression in leucocytes, in particular genes involved in chemotaxis, adhesion or infiltration<sup>(29)</sup>.

Gene expression analysis in endothelial cells using TaqMan low-density arrays suggested that flavanones could affect endothelial function through transcriptional regulation of gene expression. Genes whose expression was identified as modulated by TNF-α are involved in different cellular processes, such as cell adhesion (ICAM-1 and CDH5), inflammation and chemotaxis (NFKB1 and CCL2) or cytoskeleton organisation (ACTR2, EZR and RAC-1). This observed effect of TNF-α on gene expression has been previously reported<sup>(30)</sup>. Exposure of endothelial cells to flavanones, aglycones or to their metabolites resulted in changes in expression of genes. Most of the modulated genes are involved in various cellular processes, including cell adhesion, cytoskeleton organisation, inflammation and chemotaxis, all being related to atherogenesis. Clustering of gene expression profiles revealed a specific pattern of gene expression in HUVEC activated by TNF-α. Interestingly, genes whose expression was up-regulated by TNF-α seemed to be down-regulated by flavanones and vice versa (Fig. 4). This observation revealed the potency of flavanone metabolites, at physiologically relevant concentrations, to counteract the effect induced by an inflammatory stimulus (TNF-α). As a result, genes related to inflammation could be the molecular targets associated with the reduction of monocyte adhesion to endothelial cells exposed to flavanone metabolites.

The inflammation process plays a critical role in atherosclerosis development through the recruitment of immune cells to the inflammatory site, particularly by triggering the synthesis of adhesion and chemotactic molecules. The present study showed that exposure of endothelial cells to flavanones, aglycones or metabolites induced an anti-inflammatory profile, as revealed by a down-regulation of expression of genes coding for inflammatory mediators, genes whose expression has been induced by TNF-α. NFKB1 gene expression was down-regulated by H3/S, N7G, H and H7G compared with the TNF-α-stimulated control. NFKB1 encodes for a NF-κB subunit, the well-known transcription factor involved in inflammation and activated by TNF- $\alpha^{(31)}$ . In agreement with the decreased expression of NFKB1 gene in response to flavanones, a trend towards the down-regulation of some of its target genes, like CCL2 (also called monocyte chemotactic protein-1 and involved in the chemotaxy of monocytes to endothelial cells) or Traf1 (one member of the TNF- $\alpha$  receptor)<sup>(32,33)</sup> is observed. In addition, pre-exposure of endothelial cells to flavanones, aglycones or metabolites also affected the expression of genes coding for adhesion molecules, which constitute other targets of NF-κB. For example, flavanones decreased expression of genes coding for adhesion

molecules like CD99 or ITGB1 and tended to reduce the expression of genes coding for E-selectin, ICAM-1 and VCAM-1 when compared with the TNF- $\alpha$ -stimulated control. These adhesion molecules participate in the rolling and firm adhesion of leucocytes to activated endothelium, and their down-regulation result in the impairment of monocyte adhesion to endothelial cells<sup>(14)</sup>. Overall, these results suggest that flavanones could inhibit inflammatory process through changes in the expression of inflammation-related genes. These genomic effects of flavanones could be, at least partially, mediated by their capacity to affect the expression of the NF-kB transcription factor. This hypothesis is supported by other studies which have previously shown the ability of flavanones to suppress NF-kB activation and related gene expression in rat kidneys or activated macrophages (34-36).

Leucocyte adhesion on activated endothelium promotes the remodelling of the apical endothelial plasma membrane into actin-rich projections that surround adherent leucocytes, known as a docking structure (37). These transmigratory cups participate in firm adhesion of monocytes to the endothelial cells and serve as directional guides for leucocytes to cross the endothelium<sup>(38)</sup>. These features of the actin cytoskeleton are also regulated by a cohort of actin-associated cytoskeletal proteins, such as talin, vinculin or cofilin. The complex constituted by ICAM-1 and VCAM-1 associated to ERM proteins (EZR, radixin and moesin) initiates intracellular signalling, such as activation of the small GTPase pathway<sup>(37,39)</sup>. Interestingly, TLDA analysis revealed that, when compared with the TNF- $\alpha$ -stimulated control, pre-exposure of endothelial cells to flavanones also down-regulated the expression of genes coding for ERM proteins: EZR, moesin and small GTPase members. In response to flavanones, the down-regulation of EZR reached significance for H3'S, N7G and N4'G and that of moesin for H3'S, H and N4'G. Pre-exposure of HUVEC to flavanones also resulted in a decreased expression of RAC1, a member of the rho family of small GTPase and whose inhibition reduces leucocyte extravasation (37,39,40). RAC signalling is known to lead to actin polymerisation through the activation of actin-related protein (ARP) 2/3 complex<sup>(41)</sup>, which in turn allows transmigration (42). Interestingly, the present study also showed that most of the studied flavanone compounds significantly down-regulated the expression of both ARP2 and ARP3 genes coding for ACTR2 and ACTR3 proteins, which are major constituents of the ARP2/3 complex. Furthermore, gene expression analysis revealed differentially expressed genes involved in cytoskeleton organisation. Using Western blot analysis, we examined expression of vinculin, a protein involved in cytoskeleton organisation and remodelling. This analysis revealed a decrease in vinculin protein level in endothelial cells pre-exposed to flavanone metabolites (Fig. 5). Overall, the reduced gene expression of actin cytoskeleton, docking structure components, cytoskeleton organisation or their regulators by flavanones (aglycones and their metabolites) might result in decreased transmigratory cups formation and consequently lead to a lower monocyte adhesion to endothelial cells and transendothelial migration.



In conclusion, the present study reveals that at physiologically achievable concentrations, the flavanone metabolites present in human plasma following citrus fruit consumption retain the ability to decrease monocyte adhesion to TNF- $\alpha$ -stimulated endothelial cells. These metabolites also present potency to modulate expression of genes, particularly those coding for cell adhesion molecules, chemokines and cytoskeleton components that are involved in monocyte adhesion and recruitment in the vascular wall. The observed modulation of gene expression at the transcriptional level by flavanones might be related to the decreased adhesion of monocytes to endothelial cells. These data give an insight into potential cellular and molecular mechanisms responsible for the athero-protective effects of dietary flavanones reported in vivo.

#### Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0007114512005454

#### **Acknowledgements**

We would like to thank Christiane Deval for TLDA experiments and Nicolas Gerard for Western blot analysis. We thank UNIJUS, the French association of fruit juice producers, who followed and communicated about this research programme. A. C. contributed to the conception and design of the study, acquisition, analysis and interpretation of data; writing the article and the final approval of the manuscript. D. M. contributed to the conception and design of the study, acquisition, analysis and interpretation of gene expression data; writing the article and the final approval of the manuscript. S. C. contributed to the Western blot analyses, writing the article and the final approval of the manuscript. J. A. M. M. contributed to the conception of the study, analysis and interpretation of cell adhesion data; writing the article and the final approval of the manuscript. M. K. K. contributed to the conception of the study, production and analysis of metabolites and the final approval of the manuscript. N. R. contribution to the conception of the study, production and analysis of metabolites and the final approval of the manuscript. S. S. contributed to the conception of the study, production and analysis of metabolites and the final approval of the manuscript. A. M. B. contributed to the development of the study protocol, revising of the article and the final approval of the manuscript. C. B.-P. contributed to the development of the study protocol, critical revising of the article and the final approval of the manuscript. A. M. contributed to the development of the study protocol, statistical analysis of the data and the final approval of the manuscript. C. M. contributed to the conception and design of the study, analysis and interpretation of data; writing the article and the final approval of the version to be published. The authors do not have financial/commercial conflict of interest. This project has received funding from the French National Research Agency in the context of the National Program for Research on Food and Nutrition (PNRA).



#### References

- 1. Widlansky ME, Gokce N, Keaney JF Jr, et al. (2003) The clinical implications of endothelial dysfunction. I Am Coll Cardiol 42, 1149-1160.
- Sima AV, Stancu CS & Simionescu M (2009) Vascular endothelium in atherosclerosis. Cell Tissue Res 335, 191-203.
- Lusis AJ (2000) Atherosclerosis. Nature 407, 233-241.
- Dauchet L, Amouvel P & Dallongeville J (2005) Fruit and vegetable consumption and risk of stroke - a meta-analysis of cohort studies. Neurology 65, 1193-1197.
- Dauchet L, Amouyel P, Hercberg S, et al. (2006) Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 136, 2588-2593.
- 6. Arts ICW & Hollman PCH (2005) Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 81, 317s-325s.
- Auclair S, Milenkovic D, Besson C, et al. (2009) Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 204, e21-e27.
- Mink PJ, Scrafford CG, Barraj LM, et al. (2007) Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 85, 895-909.
- Cassidy A, Rimm EB, O'Reilly EJ, et al. (2012) Dietary flavonoids and risk of stroke in women. Stroke 43, 946-951.
- Morand C, Dubray C, Milenkovic D, et al. (2011) Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 93, 73-80.
- Lee CH, Jeong TS, Choi YK, et al. (2001) Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 284, 681-688.
- Mulvihill EE, Assini JM, Sutherland BG, et al. (2010) Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 30, 742-748.
- Chanet A, Milenkovic D, Deval C, et al. (2012) Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. I Nutr Biochem 23, 469-477.
- 14. Choi JS, Choi YJ, Park SH, et al. (2004) Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. J Nutr 134, 1013-1019.
- Nizamutdinova IT, Jeong JJ, Xu GH, et al. (2008) Hesperidin, hesperidin methyl chalone and phellopterin from Poncirus trifoliata (Rutaceae) differentially regulate the expression of adhesion molecules in tumor necrosis factor-alphastimulated human umbilical vein endothelial cells. Int Immunopharmacol 8, 670-678.
- Rizza S, Muniyappa R, Iantorno M, et al. (2011) Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 96, E782-E792.
- 17. Manach C, Scalbert A & Morand C (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727-747.
- Vallejo F, Larrosa M, Escudero E, et al. (2010) Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans. J Agric Food Chem 58, 6516–6524.
- Brett GM, Hollands W, Needs PW, et al. (2009) Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric



- variables and contraceptive pill use on flavanone excretion. Br J Nutr 101, 664-675.
- Khan MK, Rakotomanomana N, Loonis M, et al. (2010) Chemical synthesis of citrus flavanone glucuronides. I Agric Food Chem 58, 8437-8443.
- 21. Maier JA, Malpuech-Brugere C, Zimowska W, et al. (2004) Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 1689, 13-21.
- Caraux G & Pinloche S (2005) PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 21. 1280-1281.
- Chanet A, Milenkovic D, Manach C, et al. (2012) Citrus flavanones: what is their role in cardiovascular protection? J Agric Food Chem 60, 8809-8822.
- Zhang H, Park Y, Wu J, et al. (2009) Source role of TNFalpha in vascular dysfunction. Clin Sci (Lond) 116, 219-230.
- Erlund I, Meririnne E, Alfthan G, et al. (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131, 235-241.
- Erlund I, Silaste ML, Alfthan G, et al. (2002) Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr 56, 891-898.
- Tribolo S, Lodi F, Connor C, et al. (2008) Comparative effects of guercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 197, 50-56.
- de Pascual-Teresa S, Johnston KL, DuPont MS, et al. (2004) Quercetin metabolites downregulate cyclooxygenase-2 transcription in human lymphocytes ex vivo but not in vivo. I Nutr 134, 552-557.
- Milenkovic D, Deval C, Dubray C, et al. (2011) Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PLoS One 6, e26669.
- Perrot-Applanat M, Vacher S, Toullec A, et al. (2011) Similar NF-kB gene signatures in TNF- $\alpha$  treated human endothelial cells and breast tumor biopsies. PLoS One 6, e21589.

- 31. Monaco C & Paleolog E (2004) Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61, 671-682.
- Toborek M & Kaiser S (1999) Endothelial cell functions. Relationship to atherogenesis. Basic Res Cardiol 94,
- Wang CY, Mayo MW, Korneluk RG, et al. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281,
- 34. Kim JY, Jung KJ, Choi JS, et al. (2006) Modulation of the agerelated nuclear factor-kappaB (NF-kappaB) pathway by hesperetin. Aging Cell 5, 401-411.
- 35. Hamalainen M, Nieminen R, Vuorela P, et al. (2007) Antiinflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007, 45673.
- 36. Tsai SH, Lin-Shiau SY & Lin JK (1999) Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol **126**, 673-680.
- 37. Hordijk PL (2006) Endothelial signalling events during leukocyte transmigration. FEBS J 273, 4408-4415.
- Wittchen ES (2009) Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci 14, 2522-2545
- 39. van Buul JD & Hordijk PL (2004) Signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol **24**. 824-833.
- Millan J & Ridley AJ (2005) Rho GTPases and leucocyteinduced endothelial remodelling. Biochem J 385, 329-337.
- 41. Eden S, Rohatgi R, Podtelejnikov AV, et al. (2002) Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature 418, 790-793.
- Yang L, Kowalski JR, Yacono P, et al. (2006) Endothelial cell cortactin coordinates intercellular adhesion molecule-1 clustering and actin cytoskeleton remodeling during polymorphonuclear leukocyte adhesion and transmigration. J Immunol 177, 6440-6449.



#### Appendix 1. Gene abbreviations and names

18S	RNA, 18S ribosomal 0
ACE	Angiotensin I converting enzyme
ACTB	Actin, beta
ACTR2	Actin-related protein 2
ACTR3	Actin-related protein 3
AGTR1	Angiotensin II receptor, type 1
AGTR2	Angiotensin II receptor, type 2
AHR	Aryl hydrocarbon receptor
AKT1	v-akt murine thymoma viral
	oncogene homolog 1
ARG2	Arginase, type II
BCAR1	Breast cancer anti-estrogen resistance
	protein 1
BMP4	Bone morphogenetic protein 4
CAV1	Caveolin 1
CCL2	Hemokine (C-C motif) ligand 2
CD99	CD99 molecule
CDC42	Cell division control protein 42 homolog
CDH2	Cadherin-2
CDH5	Cadherin-5
CDKN1A	Cyclin-dependent kinase inhibitor 1
CLDN1	Claudin 1
CLDN5	Claudin 5
CTNNB1	Catenin (cadherin-associated protein),
	beta 1, 88 kDa
CTNNBIP1	Catenin, beta interacting protein 1
DUSP1	Dual specificity phosphatase 1
ECE1	Endothelin converting enzyme 1
EDN1	Endothelin 1
EDN2	Endothelin 2
ELAVA1	ELAV (embryonic lethal, abnormal vision,
E0D4	Drosophila)-like 1 (Hu antigen R)
ESR1	Estrogen receptor 1
EZR	Ezrin
F11R FLT1	F11 receptor Fms-related tyrosine kinase 1
GABP	GA binding protein transcription factor
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GJA4	Gap junction protein, alpha 4, 37 kDa
GPX1	Glutathione peroxidase 1
HMOX1	Heme oxygenase (decycling) 1
HSBP1	Heat shock factor binding protein 1
HSP90	Heat shock ractor binding protein 1
ICAM1	Intercellular adhesion molecule 1
IKBKB	Inhibitor of kappa light polypeptide gene
II LEI LE	enhancer in B-cells, kinase beta
IL6	Interleukin 6
IQGAP1	IQ motif containing GTPase
	activating protein 1
IQGAP2	IQ motif containing GTPase
	activating protein 2
ITGB1	Integrin, beta 1
JAM3	Junctional adhesion molecule 3
JUN	Jun proto-oncogene
KDR	Kinase insert domain receptor
KEAP1	Kelch-like ECH-associated protein 1
KLF2	Kruppel-like factor 2
LDLR	Low density lipoprotein receptor
MAPK14	Mitogen-activated protein kinase 14
MSN	Moesin
MYL12B	Myosin, light chain 12B
MYL7	Myosin, light chain 7
MVIK	Myosin light chain kingso

Myosin light chain kinase

enhancer in B-cells 1

Nitric oxide synthase 3


NADPH oxidase 1

NADPH oxidase 3

NADPH oxidase 4

Nuclear factor of kappa light polypeptide gene

Natriuretic peptide receptor A/guanylate cyclase A



NAD(P)H dehydrogenase, quinone 1 NRII2 Nuclear receptor subfamily 1, group I, member 1 OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 PDGFA Platelet-derived growth factor alpha polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphoriylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Von Willebrand factor		
group I, member 1 Oxidized low density lipoprotein (lectin-like) receptor 1 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 PDGFA Platelet-derived growth factor alpha polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphorlyase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPTB12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A	NQO1	NAD(P)H dehydrogenase, quinone 1
Oxidized low density lipoprotein (lectin-like) receptor 1 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 PDGFA Platelet-derived growth factor alpha polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 1 PTGS2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RADX Radixin RELA v-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TNF receptor-associated factor 1 VGAM1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A	NRII2	Nuclear receptor subfamily 1,
(lectin-like) receptor 1 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 PDGFA Platelet-derived growth factor alpha polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Protein tyrosine kinase 2 PTK2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RADX Radixin RELA v-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TNF receptor-associated factor 1 VASCUlar cell adhesion molecule 1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A		group I, member 1
PAK1 PAK4 PDGFA Platelet-derived growth factor alpha polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 PARA Peroxisome proliferator-activated receptor alpha PPARD PPARA Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPTGIR PTGIR PTGS1 Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 PTK2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBCA RBCA RBCA RBCA RBCA RBCA RBCA RBC	OLR1	Oxidized low density lipoprotein
PAK4 PDGFA Platelet-derived growth factor alpha polypeptide PECAM1 Platelet-derived growth factor beta polypeptide PECAM1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Prostaglandin I2 (prostacyclin) receptor PTGIS PTGS1 Prostaglandin Prostaglandin-endoperoxide synthase 1 PTGS2 PTK2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBDX RACI RBAS-related Protein Rap-1A RDX RACI RBAS-related protein Rap-1A RDX RACI RBAS-related, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide alpha Platelet-derived growth factor A Platelet-derived growth factor A Platelet-derived growth factor alpha polypeptide PECAM1 Platelet-derived growth factor alpha polypeptide PECAM1 Platelet-derived growth factor alpha polypeptide PECAM1 Platelet-derived growth factor alpha polypeptide Platelet-derived growth factor alpha polypeptide PECAM1 Platelet-derived growth factor plane polypeptide platelet-derived growth factor plane platelet-derived growth factor plane platelet-derived growth fac		(lectin-like) receptor 1
PDGFA Platelet-derived growth factor alpha polypeptide Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 1 PTGS2 Protein tyrosine kinase 2 PTK2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBAP1A RBAS-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A	PAK1	
polypeptide PDGFB Platelet-derived growth factor beta polypeptide PECAM1 Platelet/endothelial cell adhesion molecule 1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha Peroxisome proliferator-activated receptor delta PPARD Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	PAK4	
PDGFB Platelet-derived growth factor beta polypeptide PECAM1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBAS-related protein Rap-1A RBDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A	PDGFA	
PECAM1 PHKA2 Phosphorylase kinase, alpha 2 PLA2G2A Phospholipase A2, group IIA PON2 Paraoxonase 2 PPARA Peroxisome proliferator-activated receptor alpha PPARD PPARGC1A Protein phosphatase 1, regulatory subunit 12B PTGIS Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin-endoperoxide synthase 1 PTGS2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 RIGHA ROCK1 ROC	PDGFB	Platelet-derived growth factor beta
PHKA2       Phosphorylase kinase, alpha 2         PLA2G2A       Phospholipase A2, group IIA         PON2       Paraoxonase 2         PPARA       Peroxisome proliferator-activated receptor alpha         PPARD       Peroxisome proliferator-activated receptor delta         PPARGC1A       Peroxisome proliferator-activated receptor gamma coactivator 1 alpha         PPP1R12B       Protein phosphatase 1, regulatory subunit 12B         PTGIR       Prostaglandin 12 (prostacyclin) receptor         PTGIS       Prostaglandin 12 (prostacyclin) synthase         PTGS1       Prostaglandin-endoperoxide synthase 1         PTGS2       Prostaglandin-endoperoxide synthase 2         PTK2       Protein tyrosine kinase 2         RAC1       Ras-related C3 botulinum toxin substrate 1         RAP1A       Ras-related protein Rap-1A         RDX       Radixin         RELA       v-rel reticuloendotheliosis viral oncogene homolog A         RHOA       Ras homolog family member A         ROCK1       Rho-associated, coiled-coil containing protein kinase 1         S100A3       S100 calcium binding protein A3         SELE       Selectin E         SERPINE1       Serpin peptidase inhibitor, clade E 1         SOD1       Superoxide dismutase 1         TRAF1	DECAM1	
PLA2G2A         Phospholipase A2, group IIA           PON2         Paraoxonase 2           PPARA         Peroxisome proliferator-activated receptor alpha           PPARD         Peroxisome proliferator-activated receptor delta           PPARGC1A         Peroxisome proliferator-activated receptor gamma coactivator 1 alpha           PPP1R12B         Protein phosphatase 1, regulatory subunit 12B           PTGIR         Prostaglandin 12 (prostacyclin) receptor           PTGIS         Prostaglandin 12 (prostacyclin) synthase           PTGS1         Prostaglandin-endoperoxide synthase 1           PTGS2         Prostaglandin-endoperoxide synthase 2           PTK2         Prostaglandin-endoperoxide synthase 2           PTK2         Prostaglandin-endoperoxide synthase 2           PTK2         Prostaglandin-endoperoxide synthase 2           RAC1         Ras-related C3 botulinum toxin substrate 1           RAP1A         Ras-related protein Rap-1A           RDX         Radixin           RELA         v-rel reticuloendotheliosis viral oncogene homolog A           RHOA         Ras homolog family member A           ROCK1         Rho-associated, coiled-coil containing protein kinase 1           S100A3         S100 calcium binding protein A3           SELE         Selectin E		
PON2 PPARA PPARA Peroxisome proliferator-activated receptor alpha PPARD Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Protein tyrosine kinase 2 PTK2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RADX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA RAS homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular endothelial growth factor A		
PPARA PPARD Peroxisome proliferator-activated receptor alpha PPARGC1A PPARGC1A Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin 12 (prostacyclin) receptor PTGIS Prostaglandin 12 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RADX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 Vascular endothelial growth factor A		
PPARD PPARGC1A Peroxisome proliferator-activated receptor delta PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPD1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 VEGFA Vascular endothelial growth factor A	-	
PPARGC1A Peroxisome proliferator-activated receptor gamma coactivator 1 alpha PPP1R12B Protein phosphatase 1, regulatory subunit 12B PTGIR Prostaglandin I2 (prostacyclin) receptor PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A RBX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 TRAF1 TNF receptor-associated factor 1 VCAM1 VEGFA Vascular endothelial growth factor A		
coactivator 1 alpha  PPP1R12B Protein phosphatase 1, regulatory subunit 12B  PTGIR Prostaglandin I2 (prostacyclin) receptor  PTGIS Prostaglandin I2 (prostacyclin) synthase  PTGS1 Prostaglandin-endoperoxide synthase 1  PTGS2 Prostaglandin-endoperoxide synthase 2  PTK2 Protein tyrosine kinase 2  RAC1 Ras-related C3 botulinum toxin substrate 1  RAP1A Ras-related protein Rap-1A  RDX Radixin  RELA V-rel reticuloendotheliosis viral oncogene homolog A  RHOA Ras homolog family member A  ROCK1 Rho-associated, coiled-coil containing protein kinase 1  S100A3 S100 calcium binding protein A3  SELE Selectin E  SERPINE1 Serpin peptidase inhibitor, clade E 1  SOD1 Superoxide dismutase 1  TRAF1 TNF receptor-associated factor 1  VCAM1 Vascular cell adhesion molecule 1  VEGFA		
subunit 12B  PTGIR Prostaglandin I2 (prostacyclin) receptor  PTGIS Prostaglandin I2 (prostacyclin) synthase  PTGS1 Prostaglandin-endoperoxide synthase 1  PTGS2 Prostaglandin-endoperoxide synthase 2  PTK2 Protein tyrosine kinase 2  RAC1 Ras-related C3 botulinum toxin     substrate 1  RAP1A Ras-related protein Rap-1A  RDX Radixin  RELA v-rel reticuloendotheliosis viral oncogene     homolog A  RHOA Ras homolog family member A  ROCK1 Rho-associated, coiled-coil containing protein     kinase 1  S100A3 S100 calcium binding protein A3  SELE Selectin E  SERPINE1 Serpin peptidase inhibitor, clade E 1  SOD1 Superoxide dismutase 1  TRAF1 TNF receptor-associated factor 1  VCAM1 Vascular cell adhesion molecule 1  VEGFA		coactivator 1 alpha
PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Radixin RELA v-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular endothelial growth factor A	PPP1R12B	
PTGIS Prostaglandin I2 (prostacyclin) synthase PTGS1 Prostaglandin-endoperoxide synthase 1 PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Radixin RELA v-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular endothelial growth factor A	PTGIR	Prostaglandin I2 (prostacyclin) receptor
PTGS2 Prostaglandin-endoperoxide synthase 2 PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular endothelial growth factor A	PTGIS	
PTK2 Protein tyrosine kinase 2 RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA	PTGS1	Prostaglandin-endoperoxide synthase 1
RAC1 Ras-related C3 botulinum toxin substrate 1 RAP1A Ras-related protein Rap-1A RDX Radixin RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	PTGS2	
substrate 1  RAP1A Ras-related protein Rap-1A  RDX Radixin  RELA v-rel reticuloendotheliosis viral oncogene homolog A  RHOA Ras homolog family member A  ROCK1 Rho-associated, coiled-coil containing protein kinase 1  S100A3 S100 calcium binding protein A3  SELE Selectin E  SERPINE1 Serpin peptidase inhibitor, clade E 1  SOD1 Superoxide dismutase 1  TRAF1 TNF receptor-associated factor 1  VCAM1 Vascular cell adhesion molecule 1  VEGFA Vascular endothelial growth factor A	PTK2	Protein tyrosine kinase 2
RDX RELA V-rel reticuloendotheliosis viral oncogene homolog A RHOA ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	RAC1	
RELA v-rel reticuloendotheliosis viral oncogene homolog A RHOA Ras homolog family member A ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	RAP1A	Ras-related protein Rap-1A
homolog A  RHOA  ROCK1  Rho-associated, coiled-coil containing protein kinase 1  S100A3  S100 calcium binding protein A3  SELE  Selectin E  SERPINE1  Serpin peptidase inhibitor, clade E 1  SOD1  SUperoxide dismutase 1  TRAF1  TNF receptor-associated factor 1  VCAM1  VEGFA  Vascular endothelial growth factor A	RDX	Radixin
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	RELA	
kinase 1  S100A3 S100 calcium binding protein A3  SELE Selectin E  SERPINE1 Serpin peptidase inhibitor, clade E 1  SOD1 Superoxide dismutase 1  TRAF1 TNF receptor-associated factor 1  VCAM1 Vascular cell adhesion molecule 1  VEGFA Vascular endothelial growth factor A	RHOA	Ras homolog family member A
S100A3 S100 calcium binding protein A3 SELE Selectin E SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	ROCK1	Rho-associated, coiled-coil containing protein
SELE Selectin E  SERPINE1 Serpin peptidase inhibitor, clade E 1  SOD1 Superoxide dismutase 1  TRAF1 TNF receptor-associated factor 1  VCAM1 Vascular cell adhesion molecule 1  VEGFA Vascular endothelial growth factor A	S100A3	
SERPINE1 Serpin peptidase inhibitor, clade E 1 SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A		
SOD1 Superoxide dismutase 1 TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A	-	
TRAF1 TNF receptor-associated factor 1 VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A		
VCAM1 Vascular cell adhesion molecule 1 VEGFA Vascular endothelial growth factor A		
VEGFA Vascular endothelial growth factor A		
	-	



MYLK

NFKB1

NOS3

NOX1

NOX3

NOX4

NPR1